EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Calpain in Traumatic Brain Injury: From Cinderella to Central Player

Carla Schallerer, Stephan Neuschmid, Barbara E Ehrlich iD, Declan McGuone iD

Cells · 14.08.2025 · 14 (16) · 1253

DOI: 10.3390/cells14161253 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 14.08.2025. Verfasst von Carla Schallerer und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany. Hauptthemen laut MEDLINE: Calpain, Brain Injuries, Traumatic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traumatic Brain Injury (TBI) is a major global health concern and a leading cause of death and disability, especially in young adults. It triggers complex secondary injury cascades, e.g., calcium dysregulation, mitochondrial dysfunction and protease activation, that extend well beyond the initial mechanical insult to drive ongoing neurodegeneration. The calcium-dependent protease calpain has emerged as a central mediator of TBI cellular pathology. Calpain cleaves a broad range of cytoskeletal and regulatory proteins across neuronal compartments, disrupting axonal integrity, synaptic function and calcium homeostasis. Despite decades of research, calpain remains an elusive therapeutic target. In this review, we examine the spatial and temporal patterns of calpain activation in the traumatically injured brain, categorize key calpain substrates by structure and location, and assess their mechanistic roles in TBI pathology. We also review recent advances in next-generation calpain-2 selective inhibitors with enhanced specificity and preclinical efficacy and discuss the emerging use of calpain-cleaved protein fragments such as SBDP145 and SNTF as candidate biomarkers for TBI diagnosis and progression. Drawing on molecular, preclinical, and clinical data, we argue that calpain warrants renewed attention as both a therapeutic target and mechanistic biomarker in TBI. It may be time for Cinderella to leave the basement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalpainBrain Injuries, TraumaticHumansAnimalsBiomarkers

Stichwörter der Autor:innen

SNTFTraumatic Brain Injuryaxon degenerationcalcium dysregulationcalpain-2 inhibitorsexcitotoxicityneurodegenerationneuropathologyspectrintherapeutics

Substanzen

CalpainBiomarkers

Autor:innen und Institutionen

  • School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.
  • Department of Pharmacology, Yale School of Medicine, New Haven, CT 06510, USA.
  • Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

ORCID-Profile: Barbara E Ehrlich, Declan McGuone

Zitieren

APA

Schallerer, C., Neuschmid, S., Ehrlich, B. E., & McGuone, D. (2025). Calpain in Traumatic Brain Injury: From Cinderella to Central Player. Cells, 14(16), 1253. https://doi.org/10.3390/cells14161253

Vancouver

Schallerer C, Neuschmid S, Ehrlich BE, McGuone D. Calpain in Traumatic Brain Injury: From Cinderella to Central Player. Cells. 2025;14(16):1253. doi:10.3390/cells14161253

BibTeX
@article{Schallerer2025,
  author = {Schallerer, Carla and Neuschmid, Stephan and Ehrlich, Barbara E and McGuone, Declan},
  title = {Calpain in Traumatic Brain Injury: From Cinderella to Central Player},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {16},
  pages = {1253},
  doi = {10.3390/cells14161253}
}
Kostenlos starten →